Novartis Pluvicto™ approved by FDA

Novartis, a member of Bio Nebraska, announced that the FDA approved Pluvicto, a targeted radioligand therapy (RLT) for eligible patients with metastatic castration-resistant prostate cancer. Pluvicto is expected to be available to physicians and patients within weeks. Read more